Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts.
Rijsbergen M, Niemeyer-van der Kolk T, Hogendoorn G, Kouwenhoven S, Lemoine C, Klaassen ES, de Koning M, Beck S, Bouwes Bavinck JN, Feiss G, Burggraaf J, Rissmann R. Rijsbergen M, et al. Among authors: burggraaf j. Br J Dermatol. 2019 May;180(5):1058-1068. doi: 10.1111/bjd.17583. Epub 2019 Mar 7. Br J Dermatol. 2019. PMID: 30580460 Free PMC article. Clinical Trial.
Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.
Vlaming ML, van Duijn E, Dillingh MR, Brands R, Windhorst AD, Hendrikse NH, Bosgra S, Burggraaf J, de Koning MC, Fidder A, Mocking JA, Sandman H, de Ligt RA, Fabriek BO, Pasman WJ, Seinen W, Alves T, Carrondo M, Peixoto C, Peeters PA, Vaes WH. Vlaming ML, et al. Among authors: burggraaf j. Clin Pharmacol Ther. 2015 Aug;98(2):196-204. doi: 10.1002/cpt.131. Epub 2015 May 19. Clin Pharmacol Ther. 2015. PMID: 25869840 Clinical Trial.
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.
van Poelgeest EP, Hodges MR, Moerland M, Tessier Y, Levin AA, Persson R, Lindholm MW, Dumong Erichsen K, Ørum H, Cohen AF, Burggraaf J. van Poelgeest EP, et al. Among authors: burggraaf j. Br J Clin Pharmacol. 2015 Dec;80(6):1350-61. doi: 10.1111/bcp.12738. Epub 2015 Oct 24. Br J Clin Pharmacol. 2015. PMID: 26261033 Free PMC article. Clinical Trial.
Injection site reactions after subcutaneous oligonucleotide therapy.
van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J. van Meer L, et al. Among authors: burggraaf j. Br J Clin Pharmacol. 2016 Aug;82(2):340-51. doi: 10.1111/bcp.12961. Epub 2016 May 31. Br J Clin Pharmacol. 2016. PMID: 27061947 Free PMC article. Review.
Renal Effects of Antisense-Mediated Inhibition of SGLT2.
van Meer L, Moerland M, van Dongen M, Goulouze B, de Kam M, Klaassen E, Cohen A, Burggraaf J. van Meer L, et al. Among authors: burggraaf j. J Pharmacol Exp Ther. 2016 Nov;359(2):280-289. doi: 10.1124/jpet.116.233809. Epub 2016 Sep 7. J Pharmacol Exp Ther. 2016. PMID: 27605629 Clinical Trial.
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R. Balak DM, et al. Among authors: burggraaf j. Clin Immunol. 2017 Jan;174:63-72. doi: 10.1016/j.clim.2016.09.015. Epub 2016 Nov 20. Clin Immunol. 2017. PMID: 27876460 Clinical Trial.
295 results